Literature DB >> 32559499

Peptide-Based PROTAC: The Predator of Pathological Proteins.

Yan Zi Au1, Tingjian Wang1, Logan H Sigua1, Jun Qi2.   

Abstract

Qu et al. (2020) demonstrate a peptide-induced targeted degradation of the alpha-synuclein protein, a hallmark of Parkinson's disease. Using a modular three-component design, the target-protein-specific, cell-permeable peptide disposed of alpha-synuclein via the ubiquitin-proteasome pathway rather than the standard autophagy-lysosome pathway.
Copyright © 2020 Elsevier Ltd. All rights reserved.

Entities:  

Year:  2020        PMID： 32559499     DOI： 10.1016/j.chembiol.2020.06.002

Source DB:  PubMed          Journal:  Cell Chem Biol        ISSN： 2451-9448            Impact factor:   8.116


  6 in total

Review 1.  Exploring the Role of Ubiquitin-Proteasome System in Parkinson's Disease.

Authors:  Tapan Behl; Sachin Kumar; Ziyad M Althafar; Aayush Sehgal; Sukhbir Singh; Neelam Sharma; Vishnu Nayak Badavath; Shivam Yadav; Saurabh Bhatia; Ahmed Al-Harrasi; Yosif Almoshari; Mohannad A Almikhlafi; Simona Bungau
Journal:  Mol Neurobiol       Date:  2022-05-03       Impact factor: 5.590

2.  Is PROTAC technology really a game changer for central nervous system drug discovery?

Authors:  Kayla Farrell; Timothy J Jarome
Journal:  Expert Opin Drug Discov       Date:  2021-04-19       Impact factor: 7.050

Review 3.  Non-small molecule PROTACs (NSM-PROTACs): Protein degradation kaleidoscope.

Authors:  Sinan Ma; Jianai Ji; Yuanyuan Tong; Yuxuan Zhu; Junwei Dou; Xian Zhang; Shicheng Xu; Tianbao Zhu; Xiaoli Xu; Qidong You; Zhengyu Jiang
Journal:  Acta Pharm Sin B       Date:  2022-02-26       Impact factor: 14.903

4.  Peptide-based PROTAC degrader of FOXM1 suppresses cancer and decreases GLUT1 and PD-L1 expression.

Authors:  Kun Wang; Xiaoyong Dai; Albert Yu; Chunyan Feng; Kewei Liu; Laiqiang Huang
Journal:  J Exp Clin Cancer Res       Date:  2022-09-29

5.  A nano-predator of pathological MDMX construct by clearable supramolecular gold(I)-thiol-peptide complexes achieves safe and potent anti-tumor activity.

Authors:  Siqi Yan; Jin Yan; Dan Liu; Xiang Li; Qianyan Kang; Weiming You; Jinghua Zhang; Lei Wang; Zhiqi Tian; Wuyuan Lu; Wenjia Liu; Wangxiao He
Journal:  Theranostics       Date:  2021-05-03       Impact factor: 11.556

Review 6.  Emerging protein degradation strategies: expanding the scope to extracellular and membrane proteins.

Authors:  Jiayi Lin; Jinmei Jin; Yiwen Shen; Lijun Zhang; Gang Gong; Huiting Bian; Hongzhuan Chen; Dale G Nagle; Ye Wu; Weidong Zhang; Xin Luan
Journal:  Theranostics       Date:  2021-07-13       Impact factor: 11.556
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.